LLY

1,040.03

+0.29%↑

JNJ

243.3

-0.53%↓

ABBV

231.41

+1.75%↑

NVS

162.81

+1.21%↑

MRK

121.33

+1.83%↑

LLY

1,040.03

+0.29%↑

JNJ

243.3

-0.53%↓

ABBV

231.41

+1.75%↑

NVS

162.81

+1.21%↑

MRK

121.33

+1.83%↑

LLY

1,040.03

+0.29%↑

JNJ

243.3

-0.53%↓

ABBV

231.41

+1.75%↑

NVS

162.81

+1.21%↑

MRK

121.33

+1.83%↑

LLY

1,040.03

+0.29%↑

JNJ

243.3

-0.53%↓

ABBV

231.41

+1.75%↑

NVS

162.81

+1.21%↑

MRK

121.33

+1.83%↑

LLY

1,040.03

+0.29%↑

JNJ

243.3

-0.53%↓

ABBV

231.41

+1.75%↑

NVS

162.81

+1.21%↑

MRK

121.33

+1.83%↑

Home・Akcijų sąrašas・Harmony Biosciences Holdings Inc

Harmony Biosciences Holdings Inc

Atidarymo kaina

SektoriusSveikatos priežiūra

36.01 0.53

Pirkti Parduoti

Apžvalga

Akcijų kainos pasikeitimas

24 val.

Dabar

Min

35.87

Max

36.16

Pagrindiniai rodikliai
By Trading Economics
Pajamos	11M 51M
Pardavimai	39M 239M
P/E Sektoriaus vid.	11.697 121.746
Pelnas, tenkantis vienai akcijai	1.08
Pelno marža	21.242
Darbuotojai	268
EBITDA	14M 73M

Rekomendacijos
By TipRanks
Rekomendacijos	Stiprus pirkimas
12 mėnesių prognozė	+31.21% upside

Dividendai
By Dow Jones
Kitas uždarbis	2026-02-24

Rinkos statistika
By TradingEconomics
Rinkos kapitalizacija	448M 2.1B
Ankstesnė atidarymo kaina	35.48
Ankstesnė uždarymo kaina	36.01

Naujienos nuotaikos

By Acuity

34%

66%

61 / 351 reitingas Healthcare

Techninis įvertinimas

By Trading Central

Pasitikėjimas

Weak Bullish Evidence

29.8 / N/A Palaikymas ir pasipriešinimas

Harmony Biosciences Holdings Inc Grafikas

Ankstesni rezultatai nėra patikimas būsimų rezultatų rodiklis.

Susijusios naujienos

2026-02-15 23:21; UTC

Įsigijimai, susijungimai, perėmimai

Qube Agrees to Takeover by MAM-Led Consortium Valuing Its Equity at $6.51 Billion

2026-02-15 23:45; UTC

Rinkos pokalbiai

Nikkei May Rise as Fears About AI Disruption Recede -- Market Talk

2026-02-15 23:40; UTC

Rinkos pokalbiai

Gold Falls on Possible Position Adjustments -- Market Talk

2026-02-15 23:06; UTC

Uždarbis

Thai Beverage: Spirits, Beer Businesses Posted Satisfactory EBITDA Growth, Alongside Profit Margin Expansion>Y92.SG

2026-02-15 23:04; UTC

Uždarbis

Thai Beverage 1Q Beer Business EBITDA THB4.64B, Up 4.7% on Year>Y92.SG

2026-02-15 23:04; UTC

Uždarbis

Thai Beverage 1Q Spirits Business EBITDA THB8.50B, Up 6.9% on Year >Y92.SG

2026-02-15 23:01; UTC

Uždarbis

Thai Beverage 1Q EBITDA THB16.75B, Up 1.8% on Year >Y92.SG

2026-02-15 23:01; UTC

Uždarbis

Thai Beverage 1Q FY Sales Revenue THB86.70B, Down 6.0% on Year>Y92.SG

2026-02-15 22:53; UTC

Įsigijimai, susijungimai, perėmimai

Qube: MAM-Led Offer Implies A$11.7 Billion Enterprise Value

2026-02-15 22:53; UTC

Įsigijimai, susijungimai, perėmimai

Qube: UniSuper to Transfer 15.07% Stake to Equivalent Ownership of Consortium Holding Structure

2026-02-15 22:52; UTC

Įsigijimai, susijungimai, perėmimai

Qube Shareholders to Receive A$5.20/Share in Cash

2026-02-15 22:52; UTC

Įsigijimai, susijungimai, perėmimai

Qube Holdings Agrees to Takeover by Macquarie Asset Management-Led Consortium

2026-02-15 22:22; UTC

Įsigijimai, susijungimai, perėmimai

BlueScope CEO Tania Archibald Speaking on a Call With Media

2026-02-15 22:17; UTC

Įsigijimai, susijungimai, perėmimai

BlueScope CEO: Stresses Whyalla Project Would Have to Make Sense to Shareholders

2026-02-15 22:16; UTC

Įsigijimai, susijungimai, perėmimai

BlueScope CEO: Some Job Cuts Inevitable to Ensure Company is Competitive

2026-02-15 22:14; UTC

Įsigijimai, susijungimai, perėmimai

BlueScope CEO: Higher Returns Tied to End of Capital Investment Program

2026-02-15 22:14; UTC

Įsigijimai, susijungimai, perėmimai

BlueScope Steel CEO: Higher Returns After Rebuffed Takeover Bid a 'Natural Coincidence'

2026-02-15 20:48; UTC

Uždarbis

BlueScope: Will Now Target Net Debt of Up to A$1.5 Billion; Will Surpass as Needed

2026-02-15 20:47; UTC

Uždarbis

BlueScope: Expects Full Benefits of Further A$150M Cost Savings in FY 2027

2026-02-15 20:46; UTC

Uždarbis

BlueScope: Recorded Net Annualized Cost Improvements of A$190 Million in 1H

2026-02-15 20:45; UTC

Uždarbis

BlueScope Expects a One-Third Lower 2H Result From Asia Business Vs 1H

2026-02-15 20:44; UTC

Uždarbis

BlueScope Expects 15% Higher 2H Result From North America Business Vs 1H

2026-02-15 20:44; UTC

Uždarbis

BlueScope Expects Lower 2H Result From Australia Business Vs 1H

2026-02-15 20:43; UTC

Uždarbis

BlueScope Expects 2H Underlying Ebit of A$620 Million-A$700 Million

2026-02-15 20:42; UTC

Uždarbis

BlueScope Net Debt A$2.2 Million at Dec. 31

2026-02-15 20:42; UTC

Uždarbis

BlueScope 1H Underlying Ebit A$557.5 Million, Up 81% On-Year

2026-02-15 20:41; UTC

Uždarbis

BlueScope 1H Underlying Ebitda A$915.3 Million, Up 39% On-Year

2026-02-15 20:40; UTC

Uždarbis

BlueScope 1H Underlying Profit A$382.0 Million Vs A$176.4 Million Year Prior

2026-02-15 20:40; UTC

Uždarbis

BlueScope 1H Sales Revenue From Continuing Ops A$8.22 Billion, Up 4% On-Year

2026-02-15 20:39; UTC

Uždarbis

BlueScope Intends to Spend A$310 Million on Buyback, Or Other Returns if Share Repurchases Limited

Akcijų palyginimas

Kainos pokytis

Harmony Biosciences Holdings Inc Prognozė

Kainos tikslas

By TipRanks

31.21% į viršų

12 mėnesių prognozė

Vidutinis 47.25 USD 31.21%

Aukščiausias 55 USD

Žemiausias 42 USD

Remiantis 5 „Wall Street“ analitikais, siūlančiais 12 mėnesių tikslines Harmony Biosciences Holdings Inc kainas – Dist per pastaruosius 3 mėnesius.

Bendras įvertinimas

By TipRanks

Stiprus pirkimas

5 ratings

Pirkti

Laikyti

Parduoti

Remiantis 5 analitikų, pateikusių Harmony Biosciences Holdings Inc akcijų reitingus – Dist per pastaruosius 3 mėnesius.

Techninis įvertinimas

By Trading Central

29.8 / N/APalaikymas ir pasipriešinimas

Bullish events outweigh bearish events.

Recent bullish events outweigh bearish events.

All events are bearish.

Rinkos nuotaikos

By Acuity

61 / 351 reitingas Sveikatos priežiūra

Finansinės naujienos

Pardavimo ir administravimo išlaidos

Veiklos sąnaudos

Ikimokestinis pelnas

Pardavimai

Pardavimo savikaina

Bendrasis pelnas iš pardavimo

Skolų palūkanų išlaidos

EBITDA

Veiklos pelnas

Apie bendrovę Harmony Biosciences Holdings Inc

Harmony Biosciences Holdings, Inc., a commercial-stage pharmaceutical company, focuses on developing and commercializing therapies for patients with rare and other neurological diseases in the United States. The company offers WAKIX (pitolisant), a molecule with a novel mechanism of action for the treatment of excessive daytime sleepiness in adult patients with narcolepsy. It also offers HBS-102, a melanin-concentrating hormone receptor 1 for MCH neurons. The company was formerly known as Harmony Biosciences II, Inc. and changed its name to Harmony Biosciences Holdings, Inc. in February 2020. Harmony Biosciences Holdings, Inc. was incorporated in 2017 and is headquartered in Plymouth Meeting, Pennsylvania.